2022
Bedside detection of intracranial midline shift using portable magnetic resonance imaging
Sheth KN, Yuen MM, Mazurek MH, Cahn BA, Prabhat AM, Salehi S, Shah JT, By S, Welch EB, Sofka M, Sacolick LI, Kim JA, Payabvash S, Falcone GJ, Gilmore EJ, Hwang DY, Matouk C, Gordon-Kundu B, RN AW, Petersen N, Schindler J, Gobeske KT, Sansing LH, Sze G, Rosen MS, Kimberly WT, Kundu P. Bedside detection of intracranial midline shift using portable magnetic resonance imaging. Scientific Reports 2022, 12: 67. PMID: 34996970, PMCID: PMC8742125, DOI: 10.1038/s41598-021-03892-7.Peer-Reviewed Original ResearchConceptsMidline shiftNeuroscience intensive care unitCare measurementYale-New Haven HospitalValuable bedside toolIntensive care unitPoor clinical outcomeBrain-injured patientsMass effectNew Haven HospitalMagnetic resonance imagingClinical outcomesIll patientsCare unitStroke patientsFunctional outcomeBedside toolObservational studyBedside detectionImaging examsPatientsResonance imagingPortable MRIImaging suiteSignificant concordance
2021
Early Inflammatory Cytokine Expression in Cerebrospinal Fluid of Patients with Spontaneous Intraventricular Hemorrhage
Ziai WC, Parry-Jones AR, Thompson CB, Sansing LH, Mullen MT, Murthy SB, Mould A, Nekoovaght-Tak S, Hanley DF. Early Inflammatory Cytokine Expression in Cerebrospinal Fluid of Patients with Spontaneous Intraventricular Hemorrhage. Biomolecules 2021, 11: 1123. PMID: 34439789, PMCID: PMC8394793, DOI: 10.3390/biom11081123.Peer-Reviewed Original ResearchConceptsIL-10IL-6IL-1βIL-8Cerebrospinal fluidIntraventricular hemorrhageDay 1IVH volumeCerebral inflammatory responsePerihematomal edema volumePro-inflammatory markersExternal ventricular drainageInflammatory cytokine expressionSpontaneous intraventricular hemorrhageChemokine ligands CCL2Tumor necrosis factorEnzyme-linked immunosorbentCSF cytokinesRelative PHELigand CCL2Obstructive hydrocephalusVentricular drainageEdema volumeCytokine expressionICH volume
2020
Fixed Compared With Autoregulation-Oriented Blood Pressure Thresholds After Mechanical Thrombectomy for Ischemic Stroke
Petersen NH, Silverman A, Strander SM, Kodali S, Wang A, Sansing LH, Schindler JL, Falcone GJ, Gilmore EJ, Jasne AS, Cord B, Hebert RM, Johnson M, Matouk CC, Sheth KN. Fixed Compared With Autoregulation-Oriented Blood Pressure Thresholds After Mechanical Thrombectomy for Ischemic Stroke. Stroke 2020, 51: 914-921. PMID: 32078493, PMCID: PMC7050651, DOI: 10.1161/strokeaha.119.026596.Peer-Reviewed Original ResearchConceptsSystolic BP thresholdMean arterial pressureArterial pressureEndovascular thrombectomyIschemic strokeSystolic BPFunctional outcomePercent timeFurther brain injuryModified Rankin ScaleBlood pressure changesPoor functional outcomeBP thresholdAutoregulatory indexHemorrhagic transformationMechanical thrombectomyRankin ScaleBlood pressureBP targetsHemodynamic managementAcute phaseBP managementStroke patientsCerebral autoregulationWorse outcomes
2013
β-Blockers associated with no class-specific survival benefit in acute intracerebral hemorrhage
Shoup JP, Winkler J, Czap A, Staff I, Fortunato G, McCullough LD, Sansing LH. β-Blockers associated with no class-specific survival benefit in acute intracerebral hemorrhage. Journal Of The Neurological Sciences 2013, 336: 127-131. PMID: 24183854, PMCID: PMC4956481, DOI: 10.1016/j.jns.2013.10.022.Peer-Reviewed Original ResearchConceptsΒ-blocker treatmentΒ-blocker useBlood pressure controlAcute intracerebral hemorrhageIntracerebral hemorrhageAdrenergic antagonistsAntihypertensive therapyPressure controlInflammation-induced injuryΒ-blocker therapyDatabase of patientsSympathetic nervous systemSpontaneous intracerebral hemorrhageAntihypertensive treatmentInpatient deathSurvival benefitImproved survivalOngoing trialsMultivariable analysisICH patientsImmune activationInpatient stayRetrospective analysisStudy populationΒ-blockers
2011
Anti-Adrenergic Medications and Edema Development after Intracerebral Hemorrhage
Sansing LH, Messe SR, Cucchiara BL, Lyden PD, Kasner SE. Anti-Adrenergic Medications and Edema Development after Intracerebral Hemorrhage. Neurocritical Care 2011, 14: 395-400. PMID: 21264527, DOI: 10.1007/s12028-010-9498-z.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic alpha-2 Receptor AgonistsAdrenergic beta-AntagonistsAgedAntihypertensive AgentsAntioxidantsBenzenesulfonatesBlood PressureBrain EdemaCerebral HemorrhageClonidineCohort StudiesCritical CareDouble-Blind MethodDrug Therapy, CombinationFemaleFree Radical ScavengersGlasgow Coma ScaleHumansMaleMiddle AgedMultivariate AnalysisProspective StudiesTreatment OutcomeConceptsIntracerebral hemorrhageClinical outcomesBlood pressure medication useAcute intracerebral hemorrhageSympathetic nervous systemAdrenergic medicationsAntihypertensive medicationsAntihypertensive treatmentMethodsThe patientsPlacebo armBlood pressureMedication useEdema volumePerihematomal edemaEdema developmentInflammatory responseLess edemaHemorrhage volumeAdrenergic activationMedicationsNervous systemMultivariate analysisEdemaHemorrhagePatients
2009
Who will participate in acute stroke trials?
Kasner SE, Del Giudice A, Rosenberg S, Sheen M, Luciano JM, Cucchiara BL, Messé S, Sansing LH, Baren JM. Who will participate in acute stroke trials? Neurology 2009, 72: 1682-1688. PMID: 19433742, PMCID: PMC2683644, DOI: 10.1212/wnl.0b013e3181a55fbe.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAgedAttitude to HealthBiomedical ResearchCaregiversClinical Trials as TopicCultureData CollectionFemaleHumansInformed ConsentMaleMental CompetencyMiddle AgedPatient CompliancePatient Education as TopicPhysician-Patient RelationsProspective StudiesRisk AssessmentRisk-TakingStrokeConceptsAcute treatment trialsAcute strokeTreatment trialsClinical trialsAcute stroke treatment trialsAcute stroke clinical trialsMean age 63Stroke treatment trialsVascular risk factorsMinority of patientsAcute stroke trialsStroke clinical trialsNovel therapeutic agentsStroke severityClinical factorsPrimary outcomeStroke trialsAcute trialProspective surveyTrial interventionRisk factorsStroke typeHigh incidenceAge 63PatientsPrior antiplatelet use does not affect hemorrhage growth or outcome after ICHSYMBOL
Sansing LH, Messe SR, Cucchiara BL, Cohen SN, Lyden PD, Kasner SE. Prior antiplatelet use does not affect hemorrhage growth or outcome after ICHSYMBOL. Neurology 2009, 72: 1397-1402. PMID: 19129506, PMCID: PMC2677505, DOI: 10.1212/01.wnl.0000342709.31341.88.Peer-Reviewed Original ResearchMeSH KeywordsAgedBrainBrain EdemaCausalityCerebral HemorrhageDisease ProgressionDrug-Related Side Effects and Adverse ReactionsFemaleHumansIatrogenic DiseaseImage Processing, Computer-AssistedMagnetic Resonance ImagingMaleMiddle AgedOutcome Assessment, Health CarePlatelet Aggregation InhibitorsProspective StudiesTomography, X-Ray ComputedTreatment OutcomeConceptsAntiplatelet medication useAntiplatelet medicationsIntracerebral hemorrhageSpontaneous intracerebral hemorrhageHemorrhage expansionMedication useClinical outcomesICH onsetHemorrhage growthTime of ICHVolume of ICHInitial ICH volumeIntracerebral hemorrhage onsetPrior antiplatelet usePlacebo-controlled trialRecent clinical trialsAssociation of useGrowth of ICHAntiplatelet useEdema growthOral anticoagulationRankin scorePlacebo armCerebral hemorrhageMultivariable analysis